
Melody Chang, R.Ph., says payers cover bispecific and CAR-T drugs but not the monitoring that lets community practices deliver them safely at lower cost.
Six states have alternative models
Arkansas-approved
Iowa-approved
Michigan-approved
Ohio-approved
Pennsylvania-pending
Utah-in state discussion
As of January 23, 2014






